logo
NasdaqGS:TSHA logo

Taysha Gene Therapies Community

NasdaqGS:TSHA Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

TSHA logo
Taysha Gene Therapies
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts

FDA Meetings And TSHA-102 Trials Will Advance Approval

Key Takeaways Advancements in TSHA-102 trials and regulatory discussions could expedite approval and boost future revenue and investor confidence. Strategic alignment with regulatory and market priorities could enhance trial success, market adoption, and long-term revenue growth.
View narrative
US$6.55
FV
71.0% undervalued intrinsic discount
120.13%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
8 days ago author updated this narrative